Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Anti-CD19 antibody
Tafasitamab
Monjuvi · TAF
Fc-engineered anti-CD19 antibody for DLBCL whose renal-relevant risks are infusion reactions and treatment-related tumor lysis rather than a direct nephropathy.
MildFc-engineered antibody era · approved 2020
Relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem-cell transplant (with lenalidomide)
Signature kidney injury
Prerenal / Hemodynamic AKI
Infusion-related reactions occur early (largely first cycle) and cytopenias are common; tumor lysis is an uncommon, treatment-related concern in responding lymphoma. Direct nephrotoxicity is not a recognized signal and AKI is secondary.
Source: Salles et al., Lancet Oncol 2020 (L-MIND)
Mechanism of kidney injury
Tafasitamab has no characteristic direct renal lesion. Its renal relevance is indirect: (1) infusion-related reactions (fever, hypotension) can transiently impair renal perfusion; (2) brisk cytoreduction in responding lymphoma can cause tumor lysis with urate/phosphate intratubular crystal nephropathy and ATN; (3) the lenalidomide partner contributes its own toxicities. The CD19 target is B-cell-restricted, so the antibody itself is not directly nephrotoxic.
Clinical presentation
Infusion reactions (chills, flushing, hypotension) chiefly during the first infusions; in responders, TLS labs (hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia) and AKI early in treatment. Otherwise a prerenal picture with intercurrent illness.
Onset
Infusion reactions early (first cycle); tumor lysis early in responders.
Reversibility
Reversible
Anticancer mechanism
Humanized, Fc-engineered (enhanced ADCC/ADCP) monoclonal antibody targeting CD19 on B cells. Combined with lenalidomide it enhances antibody-dependent cellular cytotoxicity and phagocytosis against diffuse large B-cell lymphoma.
Management
Manage infusion reactions by slowing/holding the infusion and giving supportive care/premedication; restore perfusion for any transient prerenal AKI. Treat tumor lysis with hydration, urate-lowering therapy, electrolyte correction and dialysis if refractory. Renal effects are generally reversible.
Risk factors
- High tumor burden (tumor-lysis risk)
- Pre-existing CKD and concurrent nephrotoxins
- Inadequate infusion premedication
- Volume depletion
Prevention
- Infusion premedication and slow first infusions to limit reactions
- Tumor-lysis risk assessment with hydration +/- allopurinol or rasburicase
- Maintain hydration; monitor renal function and electrolytes early
- Avoid additive nephrotoxins
Note · The renal link is indirect — infusion reactions and treatment-related tumor lysis rather than a direct lesion. Note that the lenalidomide combination partner (not tafasitamab) carries the renal dose-adjustment requirement.
Clinical depth
Renal dose adjustment
No dose adjustment for renal impairment for the antibody (not renally cleared); the lenalidomide partner does require CrCl-based dose adjustment. Manage tafasitamab interruptions for infusion reactions/cytopenias.
Dialyzability & ESKD dosing
A monoclonal antibody; not dialyzable. ESKD dosing of the antibody is not specifically established; lenalidomide needs renal dose adjustment.
Differential diagnosis
Separate infusion-reaction transient prerenal AKI from tumor-lysis crystalline nephropathy (early, in responders) and from lenalidomide-related effects. The antibody itself is not directly nephrotoxic.
Monitoring
- Vital signs during infusions (reactions)
- TLS labs in responders (uric acid, phosphate, potassium, creatinine)
- CBC per schedule (cytopenias)
- Renal function periodically (also to guide lenalidomide dosing)
Key trials & series
- L-MIND (Salles, Lancet Oncol 2020) — registrational tafasitamab + lenalidomide trial
Clinical pearls
- Tafasitamab's renal risks are infusion reactions and tumor lysis, not a direct antibody nephrotoxicity.
- Remember to renally dose-adjust the lenalidomide partner even though the antibody needs none.
- Risk-stratify responders for tumor lysis and pre-treat with hydration +/- rasburicase.
- First-cycle infusion reactions are the main acute event — premedicate and slow the infusion.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.Salles G et al. · Lancet Oncol 2020 · PMID 32511983Registrational trial establishing efficacy and the infusion-reaction/cytopenia safety profile.PMIDTafasitamab plus lenalidomide in relapsed/refractory DLBCL: 5-year results from L-MIND.Duell J et al. · Haematologica 2024 · PMID 37646664Long-term efficacy/safety confirming the toxicity profile.PMIDPhase IIa study of the anti-CD19 antibody MOR208 (tafasitamab) in relapsed or refractory B-cell non-Hodgkin lymphoma.Jurczak W et al. · Ann Oncol 2018 · PMID 29444231Early-phase safety/pharmacology of the antibody.PMIDTafasitamab: mechanism of enhanced Fc-mediated effector function.Patra-Kneuer M et al. · J Immunother Cancer 2023 · PMID 37600821Mechanistic basis of the Fc-engineered ADCC/ADCP activity.PMIDRE-MIND: comparison of tafasitamab + lenalidomide versus lenalidomide monotherapy in R/R DLBCL.Zinzani PL et al. · Clin Cancer Res 2021 · PMID 34433649Comparative effectiveness/safety context.PMIDGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.Cairo MS et al. · J Clin Oncol 2010 · PMID 20331465Consensus TLS prophylaxis/management applicable to responding lymphoma.
Related agents
Other agents sharing the same signature kidney injury.